Navigation Links
Jazz Pharmaceuticals Announces Reduction in Force to Reflect Streamlined Operations
Date:12/16/2008

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see http://www.JazzPharmaceuticals.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to the continued development of Jazz Pharmaceuticals' JZP-6 product candidate, the potential future profitability of Jazz Pharmaceuticals, and the estimated charge related to the workforce reduction. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the development of Jazz Pharmaceuticals' JZP-6 and JZP-8 product candidates, including the risk that clinical trial results may require Jazz Pharmaceuticals to discontinue their development; and risks related to the need for additional funds. These and other risk factors are discussed under "Risk Factors" in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on November 14, 2008. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... COPENHAGEN, Denmark , Sept. 16, 2014 /PRNewswire/ ... its innovative TransCon technology to address significant unmet ... its ongoing Phase 2 pediatric study to evaluate ... hormone deficiency, or GHD.  The full interim results ... of the GRS and IGF Society, being held ...
(Date:9/15/2014)... drives classical phase transitionsthink solid, liquid, and ... the temperature drops. If phase transitions occur ... mechanics reigns, subtle fluctuations can dramatically transform ... U.S. Department of Energy,s Brookhaven National Laboratory ... frigid landscape of absolute zero to isolate ...
(Date:9/15/2014)... have developed a technique for controlling the surface tension ... the door to a new generation of reconfigurable electronic ... the fact that the oxide "skin" of the metal ... as a surfactant, lowering the surface tension between the ... a liquid metal alloy of gallium and indium. In ...
(Date:9/15/2014)... IRVINE, Calif. , Sept. 15, 2014 /PRNewswire/ ... a new viral transport solution for safe ambient ... prior to molecular testing. Importantly, the infectivity of agents ... solution while maintaining the integrity of the viral ... news of the recent Ebola epidemic in ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Elusive quantum transformations found near absolute zero 2Elusive quantum transformations found near absolute zero 3Researchers control surface tension to manipulate liquid metals 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3
... programs for the University of Wisconsin-Madison, is part information technologist, ... Part II of this interview. In Part I , ... (below), he addresses creating a culture of innovation and finding ... featured speaker at the Fusion 2007 CEO-CIO Symposium . ...
... In a move that could bring additional investment partners to ... an office in Ann Arbor, Mich. after receiving money from ... which recently moved into a larger space in the MGE ... of three venture firms selected to receive funding through a ...
... - Oskar Anderson, chief information officer for the Wisconsin ... succeed Matt Miszewski as administrator of the state Division ... this week, will join the Department of Administration ... His appointment was confirmed this morning in an e-mail to ...
Cached Biology Technology:Venture Investors to open Michigan office 2Oskar Anderson to succeed Miszewski as head of state technology division 2
(Date:9/16/2014)... "molecular brakes" that time the generation of important cells ... cells" translate sound waves into electrical signals that are ... If the arrangement of the cells is disordered, hearing ... will be published in The Journal of Neuroscience ... Hey2 act as brakes to prevent hair cell generation ...
(Date:9/16/2014)... the dinosaurs 66 million years ago decimated the evergreens ... than their deciduous peers, according to a study led ... journal PLOS Biology . , Applying biomechanical ... leaves of angiosperms flowering plants excluding conifers ... of a diverse plant community thriving during a 2.2 ...
(Date:9/16/2014)... returned to Spain culminating the around the world of ... of how the global ocean works and what is ... the atmosphere is not limited to coastal areas, but ... planet, and it is already affecting the ocean ecosystem. ... CSIC Residence for Researchers in Barcelona, in a congress ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3
... research team from Rollins College in Florida and the University ... the coral-killing pathogen that causes white pox disease of Caribbean ... elkhorn coral was listed for protection under the United States ... disease. The team,s findings have just been published in the ...
... A recent study demonstrated increased rates of celiac disease ... in the May-June 2011 issue of The Journal ... patients presenting with infertility. Each participant underwent serologic ... testing. The 4 patients who had positive serum ...
... , Cincinnati, (OH) - The International Rett Syndrome Foundation ... to support eight cutting-edge projects that aim to accelerate ... IRSF is the world,s largest private source of funding ... 1998, IRSF has cumulatively funded over $24M in high ...
Cached Biology News:Human pathogen killing corals in the Florida Keys 2Human pathogen killing corals in the Florida Keys 3IRSF awards over $650,000 for Translational Rett Syndrome research 2
... Our Accumix standard is a new tuning ... electrospray ionization mass spectrometry. Accumix is ... mass range coverage for both tuning and ... and LTQ-MS) and Fourier transform mass spectrometers. ...
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Biology Products: